Related Experiment Video
Updated: Feb 20, 2026
11:34
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
2.7K
New directions in hepatitis B therapy research
Marta Lewandowska1, Anna Piekarska1
1Department of Infectious Diseases and Hepatology, Medical University in Lodz, Lodz, Poland.
Clinical and Experimental Hepatology
|October 25, 2017
Summary
Current chronic hepatitis B (CHB) treatments suppress the virus but rarely clear HBsAg or target cccDNA. New therapies are urgently needed to eradicate HBV and prevent severe liver disease complications.
Area of Science:
- Hepatology
- Virology
- Immunology
Background:
- Chronic hepatitis B (CHB) treatments offer long-term disease control but rarely achieve HBsAg clearance or target the persistent cccDNA.
- Existing therapies reduce complications like liver failure and cancer but do not eliminate the risk, even post-HBsAg seroclearance.
Purpose of the Study:
- To review the current landscape of CHB therapeutics.
- To highlight the limitations of existing treatments and the urgent need for novel approaches targeting cccDNA and immune restoration.
Main Methods:
- Review of recent experimental approaches and novel antiviral strategies.
- Analysis of therapeutic targets including different phases of the HBV life cycle, cccDNA, and host immune responses.
Main Results:
- Experimental therapies show promise against HBV infection by targeting cccDNA and modulating immune responses.
- Promising in vitro and animal model results do not always translate to human clinical efficacy.
Conclusions:
- Despite challenges, the development of multiple novel antivirals offers hope for effective CHB eradication.
- Future therapies may relieve patients from the burden of chronic hepatitis B, a potentially fatal liver disease.
